› Capital raise of $10.2m completed in November 2025 › Cash of $9.35 million at 30 June 2026 to fund operations, pipeline development and commercial initiatives › Net loss of $7.51 million for the year ended 30 June 2026 › Research and Development Tax Refund of $1.78m recognised for the 2026 financial year Financial Commercial › EXO-NET® commercial momentum maintained, with global distributor Promega placing its third EXO-NET® order and customer base expanded across US, Europe and Asia › Exclusive worldwide licence secured from UniQuest for novel exosomal ovarian cancer biomarkers, strengthening INOVIQ’s intellectual property position and diagnostics portfolio › Peter Gunzburg appointed Non-Executive Director in October 2025 and elected Chairman in December 2025, bringing over 40 years’ public company director, stockbroking and investment experience › Dr Rebecca Lim appointed CSO in January 2026, strengthening INOVIQ’s leadership team with extensive expertise in translational research and clinical development across cell and gene therapy, regenerative medicine and EV technologies Corporate Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 5 Annual Report 2026
RkJQdWJsaXNoZXIy MjE2NDg3